TX-MARY-KAY/GENDER-GAP
2.9.2022 18:01:39 CEST | Business Wire | Press release
Below is a statement by Julia A. Simon, Chief Legal and Chief Diversity & Inclusion Officer, Mary Kay Inc., on the release of the 2022 World Economic Forum’s Global Gender Gap Report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005218/en/
Julia Simon, Chief Legal Officer and Chief Diversity & Inclusion Officer (Photo Credit: Mary Kay Inc.)
According to a sobering finding from the World Economic Forum’s 2022 Global Gender Gap Report, gender parity is beyond reach in our lifetime. In fact, according to the report, it will take 132 years for gender equality to become a reality and 151 years to close the economic participation and opportunity gender gap. Not a single country from the 146 examined has reached parity.
That’s the bad news.
The good news? There’s still time to change all that. The 2022 findings have shaken me, but they have not deterred me. Nor should they deter you.
Gender equality is a prerequisite not only for human development—but sustainable economic growth. A rich body of data shows that without gender parity it is impossible to reduce poverty, attain food security, address climate impacts, or ensure a more peaceful and inclusive society. Gender parity isn’t a “nice to have.” It’s also not just a perk of developed nations. It is an essential requirement for all countries to develop and prosper.
To mitigate further backsliding, the structural barriers limiting women’s labor market participation, including their re-entry and retention in the workforce following COVID-19, must be addressed. Targeted policies which support women’s talent development in the industries of the future, and which accelerate their advancement to leadership and management positions, are also needed.
The private sector has a critical role to play in addressing gender gaps in the workplace and in developing the pipeline of women for leadership positions. As a company founded by a barrier-breaking businesswoman almost 60 years ago, this is personal to Mary Kay.
In 2019, Mary Kay signed the Women’s Empowerment Principles (WEPs) and in 2021 the company became a Commitment Maker to the Generation Equality Forum Action Coalitions to accelerate progress on gender equality to advance the Sustainable Development Goals.
Mary Kay is participating in the 2022-2023 UN Global Compact Target Gender Equality accelerator programme to continue the implementation of ambitious corporate targets for women’s representation and leadership in the company and in our supply chain. Leading by example and reflecting our belief in increased women’s inclusion, Mary Kay is putting our values and commitments into action:
Women’s Representation and Leadership at Mary Kay (Data from August 2022):
- 62% of our Global Workforce are Women
- 50% of our Executive Team are Women
- 53% of our Vice Presidents and above are Women
- 57% of our Directors and above are Women
- 59% of our Managers and above are Women
- 70% of our Market Leaders are Women
- 60% of our Leaders in our Top 10 Markets are Women
Gender-Responsive Procurement & Supplier Diversity at Mary Kay (U.S. only supply chain data from February 2021):
- 66% of our Procurement Team are Women
- 12% of our Indirect Suppliers are Women, Minority or Veteran-Owned
- 5% of our Direct Suppliers are Women, Minority or Veteran-Owned
Our 10-year Sustainability Strategy, titled Enriching Lives Today for a Sustainable Tomorrow, pursues a holistic approach to advancing gender equality and women’s empowerment with the following key commitments to achieve by 2030:
- Economically empower 5 million women worldwide
- Ensure access to education for 250,000 women and girls globally
- Provide over 10 million women worldwide with gender-based violence support services, and
- Develop a 10-year policy agenda to address women’s rights
Inspired by our mission as an entrepreneurship development company founded by a woman for women, we are committed to advancing women’s entrepreneurship and dismantling the barriers to women’s economic empowerment. We brought this vision to the United Nations in 2019 and, together with 6 UN agencies, we incepted the Women’s Entrepreneurship Accelerator (WEA) to create an enabling ecosystem for women entrepreneurs.
The time to act is now. Sitting on the sidelines and waiting 132 years is simply not an option. The Sustainable Development Impact Meeting on “Advancing Gender Equality”, which takes place in New York this month, is an opportunity for leaders from the public and private sector to identify tools and strategies to close the gender gap. We owe it to future generations to mobilize our efforts to make the transformative changes that are so badly needed for women and girls.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors of domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
